›Portfolio Companies

Past, Present and Future Leaders

The managing directors of IWHP are proud and privileged to have partnered with visionary management teams who are shaping the future of Biotech, Medical Devices and Healthcare IT. The groundbreaking businesses they have created are representative of the industry-leading companies that InterWest has helped build over the last three decades.

Our Companies

VENTURE INVESTING IN BREAKTHROUGH HEALTHCARE COMPANIES

KAI Pharmaceuticals

portfoliocompanies

company snapshot

KAI Pharmaceuticals

KAI is a clinical-stage, biopharmaceutical company whose lead peptide product candidate, KAI-4169, is in development for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD is characterized by an elevation of parathyroid hormone also referred to as secondary hyperparathyroidism. KAI was acquired by Amgen in 2012.

website
www.amgen.com
Leadership
Follow The Company
Investment Team